Education
About Us
Working with TipRanks
Follow Us
Mannkind Corp. (MNKD)
NASDAQ:MNKD
MNKD Stock Chart & Stats
Day’s Range― - ―
52-Week Range$3.38 - $7.63
Previous CloseN/A
Volume434.88K
Average Volume (3M)3.46M
Market Cap
$1.41B
Enterprise Value$1.14B
Total Cash (Recent Filing)$178.99M
Total Debt (Recent Filing)$46.82M
Price to Earnings (P/E)52.5
Beta0.71
Next Earnings
Nov 11, 2025EPS Estimate
0.02Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.00
Shares Outstanding306,828,340
10 Day Avg. Volume4,007,215
30 Day Avg. Volume3,464,737
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap0.81
Enterprise Value/Revenue3.77
Enterprise Value/Gross Profit5.04
Enterprise Value/Ebitda14.40
Forecast
1Y Price Target
$9.86Price Target Upside71.78% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
Bulls Say, Bears Say
Bulls Say
Acquisition ImpactThe acquisition of scPharmaceuticals Inc. is viewed positively for MNKD shares, as it diversifies the revenue base and provides more control over future revenues.
EarningsPositive TETON-2 data has led to an increase in the price target for MNKD shares to $11, from $9.
Revenue GrowthTyvaso demonstrated significant improvements in patients with IPF, which is beneficial for MNKD as it receives royalties on all Tyvaso DPI sales.
Bears Say
Financial ConcernsStock weakness may be due to investor concerns related to a financing agreement for up to $500M, which could be perceived as potential dilution or financial strain.
Growth DecelerationTyvaso DPI royalties reflect Q/Q deceleration in Tyvaso growth as reported, with a decrease from +11% in 1Q25 to 4% in 2Q25.
Market SkepticismThere is skepticism about the likelihood of success for TETON given the primarily vasodilative mechanism and different patient population compared to previous studies.
MannKind News
MNKD FAQ
What was Mannkind Corp.’s price range in the past 12 months?
Mannkind Corp. lowest stock price was $3.38 and its highest was $7.63 in the past 12 months.
What is Mannkind Corp.’s market cap?
Mannkind Corp.’s market cap is $1.41B.
When is Mannkind Corp.’s upcoming earnings report date?
Mannkind Corp.’s upcoming earnings report date is Nov 11, 2025 which is in 68 days.
How were Mannkind Corp.’s earnings last quarter?
Mannkind Corp. released its earnings results on Aug 06, 2025. The company reported $0 earnings per share for the quarter, missing the consensus estimate of $0.05 by -$0.05.
Is Mannkind Corp. overvalued?
According to Wall Street analysts Mannkind Corp.’s price is currently Undervalued.
Does Mannkind Corp. pay dividends?
Mannkind Corp. does not currently pay dividends.
What is Mannkind Corp.’s EPS estimate?
Mannkind Corp.’s EPS estimate is 0.02.
How many shares outstanding does Mannkind Corp. have?
Mannkind Corp. has 306,828,340 shares outstanding.
What happened to Mannkind Corp.’s price movement after its last earnings report?
Mannkind Corp. reported an EPS of $0 in its last earnings report, missing expectations of $0.05. Following the earnings report the stock price went down -13.283%.
Which hedge fund is a major shareholder of Mannkind Corp.?
Currently, no hedge funds are holding shares in MNKD
MannKind Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$9.86 (71.78% Upside)
$9.86 (71.78% Upside)
Blogger Sentiment
Bullish
MNKD Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 101.3K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 4.5%
Last 30 Days ▲ 6.5%
Last 30 Days ▲ 6.5%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-8.30%
12-Months-Change
Fundamentals
Return on Equity
-35.00%
Trailing 12-Months
Asset Growth
-7.24%
Trailing 12-Months
Company Description
Mannkind Corp.
MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes. It also promotes Thyquidity to adult and pediatric endocrinologists, and other healthcare providers for the treatment of hypothyroidism. The company has a license and collaboration agreement with United Therapeutics Corporation. It also has an agreement with NRx Pharmaceuticals to develop a dry powder formulation of ZYESAMI (aviptadil), a synthetic form of human vasoactive intestinal peptide to help protect cells against inflammatory conditions. MannKind Corporation was incorporated in 1991 and is headquartered in Westlake Village, California.
MNKD Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call presented several positive developments, including strong revenue growth from Tyvaso DPI and Afrezza, a secure financial position with non-dilutive funding from Blackstone, and advancements in key development programs. However, there were challenges, such as a decline in V-Go revenue and the need for significant investment in the pediatric launch of Afrezza. Despite these challenges, the overall sentiment is optimistic due to the strategic focus and strong financials.View all MNKD earnings summariesMNKD Stock 12 Month Forecast
Average Price Target
$9.86
▲(71.78% Upside)
Technical Analysis
Arrowhead Pharmaceuticals
―
BioCryst
―
Agios Pharma
―
Beam Therapeutics
―
Kymera Therapeutics
―
Ownership Overview
2.87% Insiders
10.99% Mutual Funds
10.69% Other Institutional Investors
62.20% Public Companies and Individual Investors